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Abstract
Background: This study focuses on exploring the relationship between changes in appetite or
eating behaviors and subsequent weight change for adult patients with schizophrenia or bipolar
disorder treated with olanzapine and adjunctive potential weight mitigating pharmacotherapy. The
aim is not to compare different weight mitigating agents, but to evaluate patients' characteristics
and changes in their eating behaviors during treatment. Identification of patient subgroups with
different degrees of susceptibility to the effect of weight mitigating agents during olanzapine
treatment may aid clinicians in treatment decisions.
Methods: Data were obtained from 3 randomized, double-blind, placebo-controlled, 16-week
clinical trials. Included were 158 patients with schizophrenia or bipolar disorder and a body mass
index (BMI) ≥ 25 kg/m2 who had received olanzapine treatment in combination with nizatidine (n
= 68), sibutramine (n = 42), or amantadine (n = 48). Individual patients were analyzed for
categorical weight loss ≥ 2 kg and weight gain ≥ 1 kg. Variables that were evaluated as potential
predictors of weight outcomes included baseline patient characteristics, factors of the Eating
Inventory, individual items of the Eating Behavior Assessment, and the Visual Analog Scale.
Results: Predictors/correlates of weight loss ≥ 2 kg included: high baseline BMI, low baseline
interest in food, and a decrease from baseline to endpoint in appetite, hunger, or cravings for
carbohydrates. Reduced cognitive restraint, increase in hunger, and increased overeating were
associated with a higher probability of weight gain ≥ 1 kg.
Conclusion: The association between weight gain and lack of cognitive restraint in the presence
of increased appetite suggests potential benefit of psychoeducational counseling in conjunction with
adjunctive pharmacotherapeutic agents in limiting weight gain during antipsychotic drug therapy.
Trial Registration: This analysis was not a clinical trial and did not involve any medical
intervention.
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Background
In adult patients with serious and persistent mental ill-
nesses such as bipolar disorder or schizophrenia, obesity
is a common comorbidity. [1] Many antipsychotic medi-
cations used to treat these diseases are associated with an
increased risk of weight gain. A meta-analysis by Allison
and colleagues showed a significantly greater incidence of
weight gain in patients treated with clozapine or olanzap-
ine compared with patients treated with other atypical
antipsychotics. [2] Since 1996, the United States (US) pre-
scribing information for olanzapine has advised clinicians
of the potential for significant weight gain in more than 1/
4 of patients during short-term therapy and in more than
1/2 of patients who receive long-term olanzapine therapy.
The current prescribing information for olanzapine warns
clinicians of the potential for short- and long-term weight
gain during treatment. [3] Treatment-emergent weight
gain may influence both the physical health of the patient
and treatment continuation. Considering the high obesity
rates in the US general population (32.9%) [4] and in
patients with schizophrenia (42%), [5] the potential risk
of weight gain needs to be evaluated carefully.
Recently, the Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) study evaluated the overall treat-
ment effectiveness of olanzapine, perphenazine, quetiap-
ine, risperidone, and ziprasidone. In this study, patients
treated with olanzapine showed the greatest treatment
effectiveness as determined by measuring the length of
time patients remained on their prescribed medication.
Patients treated with olanzapine remained on their medi-
cation statistically significantly longer compared to
patients treated with quetiapine or risperidone, but not
compared to patients treated with perphenazine or
ziprasidone. [6] However, olanzapine-treated patients
gained significantly more weight than patients in the
other treatment groups (p < .001), and significantly more
patients treated with olanzapine reported potentially clin-
ically significant weight gain ≥ 7% increase from baseline
weight (p < .001) and discontinued treatment due to
weight gain or changes in metabolic parameters (p <
.001). [6]
In light of these data, clinicians are searching for effective
strategies to help manage potential weight gain in this
patient population. While one option is to switch to
another antipsychotic medication that may have a more
favorable weight gain profile, this does not always reverse
the weight gain the patient may have already experienced.
[7] Behavioral therapy and pharmacologic treatments
have been studied as alternatives to switching antipsy-
chotic medications in order to potentially limit or reverse
weight gain during treatment with olanzapine. Recently,
Ganguli published a comprehensive review summarizing
behavioral therapy to induce weight loss in patients with
schizophrenia. [8] This review showed that non-pharma-
cologic interventions were successful in controlling
weight in some patients, and it concluded that all weight
maintenance efforts should include behavioral interven-
tions, dietary advice, and exercise. In addition, the
Cochrane Group recently conducted a comprehensive
review critically evaluating both non-pharmacologic and
pharmacologic randomized controlled trials (RCTs) of
adjunctive agents hypothesized to prevent weight gain or
to reduce weight in patients with schizophrenia who were
receiving antipsychotic treatment. Within the group of
RCTs that were included in this review, studies using cog-
nitive/behavioral therapy showed the best efficacy in
weight prevention (weighted mean difference [WMD]: -
3.38 kg) and, to a lesser extent, in weight reduction
(WMD: -1.69 kg). Pharmacological intervention studies
resulted in a more modest prevention of weight gain
(WMD: -1.16 kg). They concluded that modest weight loss
can be achieved in patients with schizophrenia by phar-
macological and non-pharmacological interventions, but
this conclusion is limited by the small number of studies
available and the substantial heterogeneity across studies.
[9]
A comprehensive review of weight mitigating agents and
their use during treatment with antipsychotics has been
published recently by Baptista and colleagues. [10]
This study focuses on pharmacological interventions and
their ability to prevent weight gain or to induce weight
loss when combined with olanzapine treatment. The aim
is neither to extract predictors for weight change during
olanzapine monotherapy nor to compare different weight
mitigating agents, but to evaluate patients' characteristics
and changes in their eating behaviors during treatment
with olanzapine and weight mitigating agents in over-
weight patients. These predictors may be useful in identi-
fying subgroups of patients who may be susceptible to the
effect of weight mitigating agents during olanzapine treat-
ment.
Previous studies of the effect of weight mitigating agents
focused on evaluating treatment difference in weight
changes, which were often statistically non-significant
[11,12] and might explain the modest effects seen in the
analysis conducted by the Cochrane Group. [9] In con-
trast, we defined categorical outcomes that constitute clin-
ically significant weight loss and weight gain during
treatment. In our opinion, these categorical analyses pro-
vide information that is clinically more useful than analy-
ses based on mean weight changes. We hypothesized that,
in patients who received weight-mitigating agents during
olanzapine treatment, the presence or absence of cogni-
tive restraint and changes in eating behaviors may both be
indicators of subsequent weight loss or weight gain. ToBMC Psychiatry 2009, 9:12 http://www.biomedcentral.com/1471-244X/9/12
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evaluate this hypothesis, and to also identify any relevant
demographic characteristics predictive of the outcome, we
performed post-hoc exploratory analyses of patients who
received olanzapine treatment in combination with 1 of 3
weight-mitigating agents (nizatidine, sibutramine, or
amantadine) in 3 Eli Lilly and Company-sponsored, pla-
cebo-controlled, weight-mitigation studies. These studies
were selected because the complete datasets allowed the
examination of potential predictors of weight change and,
therefore, could help identify patients who might or
might not be more susceptible to weight change when
receiving a pharmacologic treatment. We evaluated the
association between appetite, eating behaviors (both at
baseline and post-treatment), and weight change in
patients with schizophrenia or bipolar disorder treated
with olanzapine and an adjunctive pharmacotherapy for
the purpose of identifying potential predictors and corre-
lates for weight changes.
Methods
The analyses presented here utilize data from 3 clinical tri-
als sponsored by Eli Lilly and Company, in adult patients
with a Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition – Text Revision (DSM-IV-TR) diagno-
sis of schizophrenia, schizoaffective disorder,
schizophreniform disorder, or bipolar disorder, that
examined the effects of nizatidine, sibutramine, or aman-
tadine compared to placebo on weight change. Only data
from those 3 trials were included due to the fact that the
authors could not access additional datasets to the extent
necessary. The primary results from each study have been
previously published in peer-reviewed journals [13,14] or
as a clinical trial registry (CTR) summary (http://www.lil
lytrials.com/results/by_product/results_zyprexa.html,
Trial ID: 5102). All study protocols were reviewed and
approved by the appropriate Institutional Review Boards
at each study site before enrolling any patient. Conduct of
the studies was in accordance with the Declaration of Hel-
sinki, the US Federal Drug Administration Code of Fed-
eral Regulations (21 CFR, Part 50), and Good Clinical
Practices. All eligible participants provided written
informed consent before undergoing any study procedure
or receiving any study treatment.
Patients
From the pool of participants who were enrolled in these
3 clinical studies, patients with a baseline BMI ≥ 25 kg/m2
who were receiving treatment with olanzapine and were
randomized to 1 of the adjunctive weight-mitigating
agents or placebo were included in these analyses. In addi-
tion, the 16-week time point was used as a common end-
point. Detailed study design information, including
inclusion and exclusion criteria, can be found in the pri-
mary publications for the nizatidine and amantadine
studies [13,14] and in the CTR summary for the sibu-
tramine study (http://www.lillytrials.com/results/
by_product/results_zyprexa.html, Trial ID: 5102). The
sibutramine and the amantadine studies were designed as
weight-reduction studies (i.e., patients had already experi-
enced a pre-specified threshold of weight gain while
receiving olanzapine treatment), while the nizatidine
study evaluated weight gain prevention after initiation of
olanzapine treatment.
Nizatidine study
In this double-blind, placebo-controlled trial, 175 male
and female patients, 18–65 years of age, were randomly
allocated in a 1:1:1 ratio to receive either open-label olan-
zapine (5–20 mg/day, flexible dosing) combined with
double-blinded nizatidine (150 mg/day or 300 mg/day)
or placebo for 16 weeks. All patients had been diagnosed
with schizophrenia, schizoaffective disorder, or schizo-
phreniform disorder.
Sibutramine study
In this double-blind, placebo-controlled study, 83 male
and female patients, 18–65 years of age, were randomly
allocated to receive either open-label olanzapine (5–20
mg/day, flexible dosing) combined with double-blinded
sibutramine (3 weeks 10 mg/day, fixed dose; 3 weeks dose
adjustment 5–15 mg/day, flexible dose; 10 weeks 5–15
mg/day, fixed dose) or placebo over 16 weeks. Due to
enrollment difficulties, the study was terminated before
the original enrollment goal of 170 patients had been
met. All patients had been diagnosed with schizophrenia,
schizoaffective disorder, schizophreniform disorder, or
bipolar I disorder.
Amantadine study
In this double-blind, placebo-controlled trial, 125 male
and female patients ages 18–65 years, were randomly
assigned to receive either open-label olanzapine (5–20
mg/day, flexible dosing) combined with double-blinded
amantadine (100–300 mg/day, flexible dosing) or pla-
cebo. At the end of the 16-week study period, an 8-week
double-blind extension period followed during which
patients continued to receive open-label olanzapine and
double-blind adjunctive treatment with amantadine. All
patients met the diagnostic criteria for schizophrenia,
schizoaffective or schizophreniform disorder, or bipolar I
disorder.
Definition of Outcomes
For the purpose of these analyses, we defined a priori suc-
cessful outcome as the occurrence of ≥ 2 kg weight loss
and unsuccessful outcome as ≥ 1 kg weight gain. We dis-
criminated between weight loss and weight gain at any
time during the study versus weight loss and weight gain
sustained to the 16-week endpoint or to study discontin-
uation.BMC Psychiatry 2009, 9:12 http://www.biomedcentral.com/1471-244X/9/12
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Eating Behavior Assessment
Outcome measures included 3 eating assessment scales:
the Eating Inventory (EI), [15] the Eating Behavior Assess-
ment (EBA, a Lilly-developed scale, not validated), and
the Visual Analog Scale (VAS). Since the focus of our anal-
yses was on predictors and correlates rather than treat-
ment comparisons, clinically meaningful, non-validated
scales are acceptable explanatory variables for use in a Cox
proportional hazards regression. The EI is a 51-item ques-
tionnaire that measures 3 factors: cognitive restraint of
eating, disinhibition of eating, and susceptibility to hun-
ger. The EBA consists of 9 items and is used to determine
eating behavior during the previous week, rated from 0
("not at all," meaning the patient reported not experienc-
ing the behavior/feeling at all) to 4 ("extremely," meaning
the patient reported exceedingly experiencing the behav-
ior/feeling). The VAS is used to determine eating behavior
during the previous 24 hours and consists of 3 items
(hunger, interest in food, and appetite) rated from 0 ("not
at all," meaning the patient reported not experiencing the
behavior/feeling at all) to 10 ("extremely," meaning the
patient reported exceedingly experiencing the behavior/
feeling). Weight, VAS score, and the EBA were measured at
baseline and at Weeks 1–6, 8, 12, and 16. The EI was
assessed at baseline and at Weeks 4, 8, 12, and 16.
Statistical Analysis
For each study individually, the overall time to weight loss
or weight gain was evaluated with a Kaplan-Meier prod-
uct-limit estimator. To examine associations between
measures of craving, eating factors, and eating behaviors
and subsequent or concurrent weight loss or weight gain,
a proportional hazards Cox regression with study-specific
baseline hazard functions and time-varying covariates was
employed, with disease (psychiatric diagnosis) as one of
the baseline covariates in the model.
Important predictors and correlates were identified using
stepwise variable selection in a Cox proportional hazards
regression model. The original set of variables included
changes from baseline and baseline values for eating
scales, BMI, ethnicity, gender, and age. Only the results for
the final models selected are reported. No subgroup anal-
yses were performed discriminating between patients with
schizophrenia and those with bipolar disorder, as the
resulting sample sizes would be too small to produce
meaningful results. All statistical analyses are reported
with a significance level of p < .05.
Results
Patients
A total of 158 patients met the a priori selection criteria for
the analyses presented here. Table 1 summarizes the
patient characteristics at baseline. The nizatidine study
provided the highest number of patients (n = 68), fol-
lowed by the amantadine (n = 48) and the sibutramine (n
= 42) studies.
Eating Inventory and EBA
To better understand the relationships among the differ-
ent measures of eating behaviors and attitudes, we com-
puted pairwise correlations between the 3 factors of the EI
Table 1: Patient Characteristics at Baseline
Nizatidine
Study
(n = 68)
Sibutramine Study
(n = 42)
Amantadine Study
(n = 48)
Total
(N = 158)
Age, years; mean (SD) 43.5 (10.2) 38.7 (11.6) 40.6 (12.0) 41.3 (11.3)
Weight, kg; mean (SD) 85.1 (12.2) 99.8 (19.7) 95.1 (18.9) 92.1 (17.7)
BMI, kg/m2; mean (SD) 30.1 (3.8) 35.0 (5.7) 32.3 (5.4) 32.1 (5.2)
Age at disease onset, years; mean (SD) 25.5 (7.5) 23.6 (9.8) 24.6 (10.6) 24.7 (9.1)
BPRS; mean (SD) 21.0 (14.1)a 8.3 (6.8) 11.6 (8.3) 14.6 (12.1)
Caucasian race, % 67.6 78.6 81.3 74.7
Gender, % males 60.3 35.7 47.9 50.0
EBA Total; mean (SD) 11.4 (4.8)b 19.2 (6.2) 19.7 (7.9) 16.0 (7.4)
VAS (hunger); mean (SD) 4.2 (2.2)c 5.7 (2.3) 6.1 (2.3) 5.2 (2.4)
VAS (interest in food); mean (SD) 4.8 (2.7)c 5.4 (2.5) 6.4 (2.9) 5.4 (2.8)
VAS (appetite); mean (SD) 4.9 (2.4)c 5.9 (2.6) 6.7 (2.6) 5.7 (2.6)
Eating Inventory (cognitive restraint); mean (SD) 7.1 (4.1)b 8.1 (3.1) 7.4 (3.9) 7.5 (3.8)
Eating Inventory (disinhibition); mean (SD) 5.0 (3.0)b 8.2 (3.8) 7.4 (3.3) 6.6 (3.6)
Eating Inventory (hunger); mean (SD) 5.2 (2.9)b 8.4 (3.1) 8.3 (3.3) 7.0 (3.4)
Abbreviations: BMI = body mass index; BPRS = Brief Psychiatric Rating Scale; EBA = Eating Behaviors Assessment: total of 9 items; each item is 
rated from 0 (not at all) to 4 (extremely); EI = Eating Inventory; SD = standard deviation; VAS = Visual Analog Scale: measurements are points on a 
scale from 0 (not at all) to 10 (extremely).
an = 65
bn = 67
cn = 66BMC Psychiatry 2009, 9:12 http://www.biomedcentral.com/1471-244X/9/12
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as well as correlations between these factors and the items
from EBA. At baseline, the 3 factors of the EI had the fol-
lowing correlations within the pooled data (N = 157; 1
patient had missing data at baseline): r = .222 (p = .0051)
between factor I (Cognitive Restraint) and factor II (Disin-
hibition); r = .0025 (p = .9753) between factor I and factor
III (Hunger); and r = .675 (p < .0001) between factor II
and factor III. Note that if factor I and factor II measured
opposite items as might be assumed in a model in which
patients with more cognitive restraint have less disinhibi-
tion, one would expect a negative correlation between
these factors, whereas our results showed a mild positive
correlation (see Discussion pp.17–18).
Pearson correlations between the 3 factors of the EI with
items from the EBA at baseline are shown in Table 2.
Highly significant correlations were observed for all items
from EBA with factor III (Hunger) and significant to
highly significant correlations for most items from EBA
with factor II (Disinhibition).
Weight Outcomes
Analysis of weight outcomes within the individual studies
revealed that the highest percentage of patients who expe-
rienced successful weight loss at any time (42.9%; 18/42)
was in the sibutramine study, while the highest percentage
of patients who showed successful weight loss sustained
to endpoint (33.3%; 16/48) was in the amantadine study.
The highest percentages of weight gain were observed in
the nizatidine study, with 70.2% (47/67) of patients
showing weight gain at any time and 59.7% (40/67)
whose weight gain was sustained to endpoint (Table 3).
Figure 1 illustrates the time to weight loss (Figure 1a) and
to weight gain (Figure 1b) in the individual study popula-
tions. While Figure 1 summarizes the results, it is not
intended to suggest direct comparisons of the efficacies of
the different weight mitigating agents used in our analy-
ses.
Significant Weight Predictors
We were able to identify five significant predictors for
weight loss in patients treated with olanzapine and 1 of
the 3 weight-mitigating agents; 2 of these were baseline
variables while 3 were time-dependent variables: higher
baseline BMI, less interest in food at baseline, decrease in
appetite, decrease in cravings for carbohydrates, and
decrease in hunger (Table 4). On the other hand, 3 time-
dependent variables were significantly correlated with
weight gain in our patient cohort: decrease in cognitive
restraint, increase in hunger, and increase in overeating
(Table 5).
Discussion
In these post-hoc analyses, we examined the association
between appetite, eating behavior, and weight change for
patients with schizophrenia or bipolar disorder treated
with olanzapine and one of three potential weight miti-
gating agents: nizatidine, sibutramine, or amantadine. We
were able to extract predictors for weight loss and for
weight gain in these patients. Additionally, we analyzed
categorical weight loss and weight gain at any time during
the study, and weight change maintained to endpoint for
the individual study groups. These results varied widely
among the 3 compounds studied. The analyses presented
here did not focus on the phenomenon of weight gain as
a treatment emergent adverse event during treatment with
olanzapine, which has already been very well character-
ized. [2,3,6]
Table 2: Correlations of EI Factors with Items from EBA
Eating Behavior Assessment Items FACTOR I
"Cognitive Restraint"
FACTOR II
"Disinhibition"
FACTOR III
"Hunger"
1. How hungry have you been? 5.5 17.3a 28.5c
2. How strong has your appetite been? 3.8 17.2a 38.7c
3. Have you craved sweets or other carbohydrates? 2.2 29.2c 40.4c
4. Have you craved fatty foods? 5.6 15.9a 23.2b
5. When you finished a meal, have you felt full or satisfied? 15.3 -2.5 -21.1b
6. Does it take an excessive amount of food before you feel satisfied? 5.7 23.3b 35.3c
7. Have you been thinking about food? 15.4 41.9c 41.6c
8. Have you been overeating? 0.3 39.0c 43.9c
9. Do you feel your eating is out of control? -11.2 44.3c 43.6c
Total score 6.8 41.5c 49.2c
Abbreviations: EBA = Eating Behaviors Assessment; EI = Eating Inventory.
Values in %
Pearson correlations × 100 adjusted for study effect and baseline BMI
n = 150
ap < .05
bp < .01
cp < .001BMC Psychiatry 2009, 9:12 http://www.biomedcentral.com/1471-244X/9/12
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Predictors for Weight Loss and Weight Gain
Five variables were identified as predictors for weight loss
in patients treated with olanzapine and weight mitigating
agents, 2 of which were baseline variables that existed in
patients treated with olanzapine before the introduction
of any weight-mitigating agent. These baseline predictors
were: higher BMI and less interest in food. The other 3 pre-
dictors for weight loss were time-dependent variables that
gained significance after initiation of treatment with
weight-mitigating agents. Patients who experienced
decreases in appetite, cravings for carbohydrates, or hun-
ger were more likely to lose weight.
Interestingly, all significant predictors for weight gain in
patients treated with olanzapine and weight mitigating
agents were time-dependent variables, measured concur-
rently with weight gain after initiation of treatment.
Patients who experienced a decrease in cognitive restraint
and/or an increase in hunger and/or an increase in
overeating were more likely to gain weight. The fact that
none of the variables available prior to treatment (e.g.
patient characteristics) were significant predictors of
weight gain, suggests that identifying such patients prior
to treatment with weight-mitigating agents may be a chal-
lenging task, and underscores the importance of regular
patient monitoring during treatment.
To test the robustness of our predictor analysis, we
repeated the analysis using a subset of the original patient
population, excluding all patients from the nizatidine
group. We chose to exclude the nizatidine group for this
test, as it is the only weight gain prevention study among
the 3 studies and therefore the trial with the most poten-
tial for bias. The results confirmed BMI and interest in
food as baseline predictors for weight loss, as well as
decreases in cravings for carbohydrates and/or hunger as
time-dependent predictors for weight loss. Similarly, a
decrease in cognitive restraint and an increase in overeat-
ing were identified as predictors for weight gain. This sub-
group analysis did not yield the previously identified
decrease in appetite as a predictor for weight loss and
increase in hunger as a predictor for weight gain. Those
factors seem to be of importance for potential weight
changes in patients that have not yet experienced weight
gain, as is the case with the nizatidine group. It appears
that in patients that have already gained weight, as is the
case for patients in the amantadine and sibutramine
groups, these factors were not predictive for potential
weight loss or weight gain in response to the addition of a
weight mitigating agent. One explanation might be that
changes in appetite and hunger play a more important
role as predictors/correlates of changes in weight for
patients at earlier stages of weight gain. Once patients
have gained substantial weight, further fluctuations in
appetite or hunger do not predict weight changes, but cog-
nitive restraint and actual eating behavior seem to remain
important predictive factors. However, more comprehen-
sive analyses of larger populations of patients are needed
to validate this hypothesis.
Our finding of a decrease in cognitive restraint (the cogni-
tive control of eating) as a significant predictor for weight
gain is especially interesting considering the findings of
Khazaal and colleagues, who showed that patients with
schizophrenia present with cognitive distortions (in their
thinking about weight regulation and self control) regard-
ing weight gain when compared with control individuals.
[16] Additionally, they also demonstrated that cognitive
behavioral therapy improved binge eating symptomatol-
ogy and weight-related cognitive thinking in patients who
had gained weight during treatment with antipsychotic
drugs. These patients experienced more progressive
weight loss after cognitive behavioral therapy than control
patients. [17] To address and utilize the importance of
cognitive restraint as a predictive factor, clinically relevant
measures to monitor cognitive restraint in a given patient
need to be developed.
Recently, Lipkovich and colleagues [18] reported early
predictors of substantial weight gain in patients who were
treated with olanzapine. Their analysis revealed that
patients with bipolar disorder treated with olanzapine
who had gained 2 to 3 kg in the first 3 weeks after initia-
tion of treatment, were at higher risk for substantial
weight gain after 30 weeks of treatment. These results are
in agreement with another study that showed patients
Table 3: Summary of Weight Outcomes
Weight Loss ≥ 2 kg Weight gain ≥ 1 kg
At any time Sustained to endpoint At any time Sustained to endpoint
Nizatidine study
(n = 67)
20.9% (n = 14) 7.5% (n = 5) 70.2% (n = 47) 59.7% (n = 40)
Sibutramine study(n = 42) 42.9% (n = 18) 26.2% (n = 11) 42.9% (n = 18) 19.1% (n = 8)
Amantadine study(n = 48) 39.6% (n = 19) 33.3% (n = 16) 56.3% (n = 27) 37.5% (n = 18)
Only patients with at least 1 post-baseline measurement are included.BMC Psychiatry 2009, 9:12 http://www.biomedcentral.com/1471-244X/9/12
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Time to weight loss/gain Figure 1
Time to weight loss/gain. 1a) Kaplan-Meier estimates of cumulative probability for weight loss ≥ 2 kg, by study. 1b) Kaplan-
Meier estimates of cumulative probability for weight gain ≥ 1 kg, by study.
A
BBMC Psychiatry 2009, 9:12 http://www.biomedcentral.com/1471-244X/9/12
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with early weight gain while receiving olanzapine treat-
ment for schizophrenia, schizophreniform, or schizoaf-
fective disorder (increases of at least 2 kg in the first 3
weeks of treatment) were more likely to develop substan-
tial weight gain (>10 kg after 30 weeks) over the course of
treatment. [19] Additionally, patients who did not experi-
ence this amount of early weight gain, but had a BMI ≥ 27
kg/m2 at treatment initiation, were also at higher risk for
substantial weight gain (>10 kg) after 30 weeks of treat-
ment. [18] Similarly, lower BMI at baseline was identified
as a predictor for weight gain during treatment with antip-
sychotics in additional studies. [20,21] Identification of
the discussed risk factors may help clinicians to better
focus weight management efforts on susceptible patients.
Eating Behavior Assessment
In the analyses presented here, we utilized the 3-factor EI
developed by Stunkard and Messick. [15] Their original
work utilized 2 main cohorts, "dieters" and "free eaters",
to validate and optimize the questionnaire and factor
analysis. Comparison of our results with theirs revealed
that correlations between eating factors evaluated in our
patient sample were very similar to those in their cohort
of "free eaters" (factor I to factor II: r = .222 versus r = .19;
factor I to factor III: r = .0025 versus r = -.06; factor II to
factor III: r = .675 versus r = .73). The majority of our
patients are probably "free eaters", meaning that they do
not routinely restrict their dietary intake in order to con-
trol their body weight.
Analysis of correlations between the 3-factor EI and the
EBA yielded interesting results. While EI factor II (Disinhi-
bition) and factor III (Hunger) showed highly significant
correlations to EBA items, EI factor I (Cognitive Restraint)
was only mildly correlated to 2 EBA items ("When you
finished a meal, have you felt full or satisfied?" and "Have
Table 4: Significant Predictors of Weight Loss
Variable HR 95% CI Interpretation
Baseline BMI 1.09b 1.03–1.15 Patients with higher baseline BMI were more likely to lose weight, and 
patients with lower baseline BMI were less likely to lose weight
Baseline VAS2 (interest in food) 0.81c 0.73–0.91 Patients who had less interest in food were more likely to lose weight and 
patients who had more interest in food were less likely to lose weight
Change from baseline in appetite (EBA-2) 0.65b 0.48–0.86 Patients experiencing a decrease in appetite were more likely to lose weight 
and patients experiencing an increase in appetite were less likely to lose 
weight
Change from baseline in cravings for sweets or 
other carbohydrates (EBA-3)
0.75a 0.59–0.94 Patients experiencing decreased craving for carbohydrates were more likely 
to lose weight and patients experiencing increased craving for carbohydrates 
were less likely to lose weight
Change from baseline in hunger (VAS1) 0.87a 0.76–0.99 Patients experiencing a decrease in hunger were more likely to lose weight 
and patients experiencing an increase in hunger were less likely to lose 
weight
Abbreviations: BMI = body mass index; CI = confidence interval; EBA = Eating Behaviors Assessment; HR = hazard ratio; VAS = Visual Analog Scale.
Pooled analysis across all 3 studies
HR was adjusted for study effect and other variables included in the model
ap < .05, bp < .01, cp < .001
Table 5: Significant Predictors of Weight Gain
Variable HR 95% CI Interpretation
Change from baseline in FACTOR 1 (Cognitive Restraint) 0.81b 0.73–0.90 Patients experiencing a decrease in cognitive 
restraint were more likely to gain weight and 
patients experiencing an increase in cognitive 
restraint were less likely to gain weight.
Change from baseline in EBA-1 (Hunger) 1.32a 1.07–1.64 Patients experiencing an increase in hunger were 
more likely to gain weight and patients 
experiencing a decrease in hunger were less 
likely to gain weight.
Change from baseline in EBA-8 (Overeating) 1.28a 1.07–1.53 Patients experiencing an increase in overeating 
were more likely to gain weight and patients 
experiencing a decrease in overeating were less 
likely to gain weight.
Abbreviations: CI = confidence interval; EBA = Eating Behaviors Assessment; HR = hazard ratio.
Pooled analysis across all 3 studies
HR was adjusted for study effect and other variables included in the model (baseline BMI was also included, although it was not significant, p = .543)
ap < .01;bp < .0001BMC Psychiatry 2009, 9:12 http://www.biomedcentral.com/1471-244X/9/12
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you been thinking about food?"). It appears that the
dimension captured in factor I (Cognitive Restraint) of the
EI is poorly represented on the EBA scale. At least in the
patient population analyzed in the current study, factor I
(Cognitive Restraint) forms a complementary dimension,
it is not the opposite of factor II (Disinhibition), as the
labeling of those dimensions might suggest. The EI and
the EBA scales appear to complement one another in the
evaluation of different dimensions of eating behavior.
While it is a limitation of the current analyses that both
EBA and VAS are non-validated scales, their usage within
an exploratory analysis as presented here is appropriate as
we did not attempt to examine treatment differences with
those scales. Instead, they were used in conjunction with
EI, a validated scale, to examine correlations between
patient characteristics and susceptibility to weight change
during treatment with olanzapine and weight mitigating
agents.
Categorical Weight Gain and Weight Loss
In this analysis, we chose the occurrence of ≥ 2 kg weight
loss as an indication of a successful outcome and the
occurrence of ≥ 1 kg weight gain as a sign for an unsuccess-
ful outcome. While those cutoff points were defined with-
out prior evidence for their validity, we believe that this
categorical evaluation of the study populations allows val-
uable insights. No established cutoff criteria were availa-
ble to serve as an alternative for our arbitrary cutoff points.
Analysis of categorical weight gain and weight loss within
each of the individual study populations revealed that
patients receiving adjunctive treatment with nizatidine
showed the poorest weight control performance. This
study had the lowest percentage of patients who experi-
enced successful weight loss and the highest percentage of
patients who gained weight throughout the course of the
study. The patients treated with nizatidine had a slightly
lower baseline BMI in comparison to the other 2 study
populations, which might be an explanation for the lower
proportion of patients who experienced weight loss. Also
of note, the inclusion criteria varied between the 3 studies.
Both the amantadine and sibutramine studies required an
initial 5% to 7% weight gain while receiving olanzapine
treatment prior to study entry, but the nizatidine study did
not. The principal objective of the nizatidine study was
weight prevention when initiating olanzapine treatment.
It has been reported that patients initiated on olanzapine
may experience most of their weight gain during the first
6 to 9 months of treatment. [22] Therefore, the previously
mentioned inclusion criterion in the amantadine and sib-
utramine studies selected for patients that had potentially
already experienced initial weight gain, while the patient
population enrolled in the nizatidine study included
patients who were just initiated on olanzapine treatment.
Finally, we cannot exclude the possibility that nizatidine
is less effective than amantadine or sibutramine as a
weight-mitigating agent. Since the analysis presented here
does not represent a direct statistical comparison of all 3
adjunctive treatments, further studies are needed. How-
ever, our result is in agreement with reports in the litera-
ture that did not show strong weight loss properties of
nizatidine in double-blind, placebo-controlled studies.
[11,23]
Intervention Strategies
A limitation of the analyses presented here is that only
patients with a BMI of ≥ 25 kg/m2 were included, therefore
the results cannot be generalized to patients with a BMI of
<25 kg/m2. Additionally, the enrollment criteria for the
studies we utilized did not take into account the individ-
ual patient's stage of treatment with olanzapine. While
patients initiating olanzapine treatment may need to
focus on weight gain prevention, those patients who have
already experienced weight gain during olanzapine treat-
ment may need to focus on weight reduction.
Generally, early intervention with the goal of weight gain
prevention seems to be the more promising approach.
Several studies suggest that lifestyle modifications result-
ing in reduced caloric intake and enhanced physical activ-
ity are helpful in minimizing weight gain during
treatment with olanzapine in patients susceptible to
weight gain, [8] while these measures are not effective in
all patients. [24,25] Additionally, there are promising
reports of successful prevention of weight gain with
weight-mitigating agents in some patients. [14,26-29]
Recently, Wu and colleagues demonstrated the efficacy of
metformin in preventing weight gain temporally associ-
ated with olanzapine treatment in a randomized, placebo-
controlled trial in drug-naïve, first-episode patients with
schizophrenia. [30] However, for many patients, weight
gain has already occurred and weight reduction is needed.
This goal is more difficult to achieve. Some promising
results point to the effectiveness of behavioral therapy and
adjunctive pharmacotherapy in helping to achieve weight
reduction. [8,23,31-40] In a randomized, placebo-con-
trolled trial, metformin plus lifestyle intervention showed
the best effect on weight loss. [41] This is some of the best
empirical evidence to date for the efficacy of treating
weight gain during treatment with antipsychotics. Over-
all, both weight gain prevention and weight reduction are
important therapeutic goals in patients receiving olanzap-
ine treatment.
To the best of our knowledge, this is the first analysis
examining predictors for weight loss and weight gain in
patients treated with olanzapine and weight-mitigating
agents. Interestingly, baseline BMI has been identified in
the past as a predictor for weight gain with olanzapine
treatment, with patients with lower BMI tending to gainBMC Psychiatry 2009, 9:12 http://www.biomedcentral.com/1471-244X/9/12
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more weight during treatment with olanzapine. [21,42]
The results of our analysis indicate that weight-mitigating
agents (in particular nizatidine, amantadine and sibu-
tramine) as adjunctive treatment to olanzapine therapy
do not appear to be beneficial for all patients, but might
have therapeutic potential for some patients. Prospective
studies are needed to better identify patients who will
benefit from such treatments. In addition, we suggest that
this analytic approach may be beneficial as a secondary or
post-hoc analysis of ongoing studies with potential phar-
macologic agents to gain a better understanding of
patients who may or may not respond to a particular strat-
egy.
Clinicians can help mitigate the potential weight gain
temporally associated with olanzapine treatment by being
aware of the patient's characteristics like baseline BMI and
baseline level of interest in food, and monitoring the
patient early in treatment for weight gain, changes in
appetite or hunger, or cravings for carbohydrates, and for
reduced cognitive restraint. These factors can help the cli-
nician determine when to intervene.
Conclusion
In the present analyses we observed an association
between weight gain and reduced cognitive restraint com-
bined with increased appetite and overeating in some
patients treated with olanzapine and an adjunctive
weight-mitigating agent. This suggests that the combined
approach of psychoeducational counseling aimed at
behavior modification and pharmacologic weight-miti-
gating agents, for select patients, may be the most benefi-
cial to limit weight gain during treatment with
olanzapine. Further research in this area is warranted.
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